1.
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
by Nussenzweig, Michel C
Nature, 2009-04-02, Vol.458 (7238), p.636-640
2.
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
by Moore, Penny L
Nature medicine, 2012-11, Vol.18 (11), p.1688-1692
3.
Antibody neutralization and escape by HIV-1
by Shaw, George M
Nature (London), 2003-03-20, Vol.422 (6929), p.307-312
4.
Recommendations for measuring HIV reservoir size in cure-directed clinical trials
by Abdel-Mohsen, Mohamed
Nature medicine, 2020-09, Vol.26 (9), p.1339-1350
5.
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
by Buchbinder, Susan P, MD
The Lancet (British edition), 2008, Vol.372 (9653), p.1881-1893
6.
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
by Siliciano, Robert F
Nature medicine, 2008-07, Vol.14 (7), p.762-766
7.
Fc receptor but not complement binding is important in antibody protection against HIV
by Burton, Dennis R
Nature (London), 2007-09-06, Vol.449 (7158), p.101-104
8.
Defining total-body AIDS-virus burden with implications for curative strategies
by Estes, Jacob D
Nature medicine, 2017-11, Vol.23 (11), p.1271-1276
9.
Technologies for global health
by Howitt, Peter, MA
The Lancet (British edition), 2012, Vol.380 (9840), p.507-535
10.
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach
by Schouten, Erik J, Dr
The Lancet (British edition), 2011, Vol.378 (9787), p.282-284
11.
HIV-1 pol gene polymorphism and antiretroviral resistance mutations in treatment-naïve adult patients in French Guiana between 2006 and 2012
by Darcissac, Edith
AIDS research and human retroviruses, 2016, Vol.32 (ja), p.801-811
12.
Frequency and implications of HIV superinfection
by Redd, Andrew D, PhD
The Lancet infectious diseases, 2013, Vol.13 (7), p.622-628
13.
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects
by Buzón, Maria J
Nature medicine, 2010-04, Vol.16 (4), p.460-465
14.
Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load
by PELUSO, Michael J
AIDS (London), 2012, Vol.26 (14), p.1765-1774
15.
Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children
by Ananworanich, Jintanat
AIDS (London), 2014-04-24, Vol.28 (7), p.1015-1020
16.
Can research at the end of life be a useful tool to advance HIV cure?
by Gianella, Sara
AIDS (London), 2017-01-02, Vol.31 (1), p.1-4
17.
HIV protease inhibitor exposure predicts cerebral small vessel disease
by SOONTORNNIYOMKIJ, Virawudh
AIDS (London), 2014, Vol.28 (9), p.1297-1306
18.
HIV-associated neurocognitive disorder is associated with HIV-1 dual infection
by Wagner, Gabriel A
AIDS (London), 2016-11-13, Vol.30 (17), p.2591-2597
19.
Leishmaniasis chemotherapy—challenges and opportunities
by Croft, S.L
Clinical microbiology and infection, 2011-10, Vol.17 (10), p.1478-1483
20.
Defective proviruses rapidly accumulate during acute HIV-1 infection
by Bruner, Katherine M
Nature medicine, 2016-09, Vol.22 (9), p.1043-1049
